scholarly journals Role of the Choroidal Vascularity Index in Branch Retinal Vein Occlusion with Macular Edema

2021 ◽  
Author(s):  
Bo-Een Hwang ◽  
Mirinae Kim ◽  
Young-Hoon Park
Keyword(s):  
Regression Analysis ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Prognostic Biomarker ◽  
Strong Association ◽  
Disease Onset ◽  
Swept Source ◽  
Vein Occlusion ◽  
Endothelial Growth Factor

Abstract The purpose of this study was to assess choroidal vasculature changes in eyes with branch retinal vein occlusion (BRVO) and macular edema (ME) using the choroidal vascularity index (CVI) and evaluate the effectiveness of CVI as a prognostic biomarker. 35 patients (70 eyes) with BRVO and ME were analyzed retrospectively. Luminal and stromal areas in choroids of swept-source optical coherence tomography were calculated using the image binarization technique. The CVI was calculated as the ratio of the luminal to total choroidal area. The CVI of BRVO and ME eyes were compared with that of the unaffected fellow and post anti-vascular endothelial growth factor (VEGF) injected eyes. A regression analysis was performed on the choroidal parameters and logMAR visual acuity (VA) two years post disease onset. The CVI of BRVO and ME eyes was significantly lower than the fellow and post-injected eyes (p<0.05). The regression analysis showed a strong association between two years after logMAR VA and the CVI of fellow eyes (R2=0.433, p<0.001). No remarkable R2 values were observed in the CVI and subfoveal choroidal thickness of BRVO and ME eyes (R2=0.189, 0.155, respectively, p<0.05). Reduced CVI in BRVO and ME suggests that retinal ischemia and choroidal vascular changes might be closely related. The fellow eye CVI could be a useful supplementary prognostic biomarker.

scholarly journals Role of the choroidal vascularity index in branch retinal vein occlusion (BRVO) with macular edema

PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0258728
Author(s):  
Bo-Een Hwang ◽  
Mirinae Kim ◽  
Young-Hoon Park
Keyword(s):  
Regression Analysis ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Prognostic Biomarker ◽  
Disease Onset ◽  
Extracellular Fluid ◽  
Vein Occlusion ◽  
Choroidal Vasculature ◽  
Fellow Eyes

Purpose To assess choroidal vasculature changes in eyes with branch retinal vein occlusion (BRVO) and macular edema (ME) using the choroidal vascularity index (CVI) and evaluate the effectiveness of CVI as a prognostic biomarker. Methods 35 patients with monocular BRVO and ME were analyzed retrospectively. Luminal and stromal areas in choroids of swept-source optical coherence tomography were calculated using the image binarization technique. The CVI was calculated as the ratio of the luminal to total choroidal area. The CVI of BRVO and ME eyes were compared with that of the unaffected fellow and post anti-vascular endothelial growth factor (VEGF) injected eyes. A regression analysis was performed on the choroidal parameters, logMAR visual acuity (VA) two years post disease onset and central macula thickness (CMT). Results The CVI of BRVO and ME eyes was significantly lower than the fellow and post-injected eyes (p<0.05). The regression analysis showed a strong association between two years after logMAR VA and the CVI of fellow eyes (R2 = 0.433, p<0.001). Remarkable correlations were observed in the CVI and subfoveal choroidal thickness of BRVO and ME eyes (R2 = 0.189, 0.155, respectively, p<0.05). The CMT of diseased eyes were also significantly associated with the CVI of unaffected fellow eyes (R2 = 0.113, p<0.05). Conclusions The alteration of CVI in BRVO and ME suggests that choroidal vasculature might be affected by extracellular fluid shift and VEGF changes. The fellow eye CVI could be a useful supplementary prognostic biomarker.

scholarly journals Bevacizumab Treatment and Treatment Regimes in Branch Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 99-103
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Vascular Endothelial ◽  
Steroid Injections ◽  
Treatment Regimes ◽  
Vein Occlusion ◽  
Bevacizumab Treatment ◽  
Endothelial Growth Factor ◽  
Retinal Vein Occlusions

Macular edema secondary to retinal vein occlusions is a significant complication affecting the vision. Medical treatment of retinal vein occlusions first started with intraocular steroid injections and then enriched with intraocular Anti-VEGF (Vascular Endothelial Growth Factor) injections. But till now the length and frequency of therapy have not been defined clearly. In this review, the use of bevacizumab in the treatment of branch retinal vein occlusion and macular edema will be summarized in light of the current literature.

scholarly journals Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Keiji Inagaki ◽  
Kishiko Ohkoshi ◽  
Sachiko Ohde ◽  
Gautam A. Deshpande ◽  
Nobuyuki Ebihara ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Disease Onset ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Group I ◽  
Group Ii ◽  
Best Corrected Visual Acuity

To assess the efficacy of subthreshold micropulse diode laser photocoagulation (SMDLP) for persistent macular edema secondary to branch retinal vein occlusion (BRVO), including best-corrected visual acuity (BCVA) > 20/40, thirty-two patients (32 eyes) with macular edema secondary to BRVO were treated by SMDLP. After disease onset, all patients had been followed for at least 6 months prior to treatment. Baseline Snellen visual acuity was used to categorize the eyes as BCVA ≤ 20/40 (Group I) or BCVA > 20/40 (Group II). Main outcome measures were reduction in central macular thickness (CMT) in optical coherence tomography (OCT) and BCVA at 6 months. In the total subject-pool at 6 months, BCVA had not changed significantly but CMT was significantly reduced. Group I exhibited no significant change in CMT at 3 months but exhibited significant reductions at 6 and 12 months. Group II exhibited a marginally significant reduction in CMT at 3 months and a significant reduction at 6 months. In patients with persistent macular edema secondary to BRVO, SMDLP appears to control macular edema with minimal retinal damage. Our findings suggest that SMDLP is an effective treatment method for macular edema in BRVO patients with BCVA > 20/40.

Intraocular Injections of Ranibizumab in Patients with Macular Edema Following Branch Retinal Vein Occlusion

2020 ◽  
pp. 127-132
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Controlled Trial ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Vein Occlusion ◽  
Endothelial Growth Factor ◽  
First Line Treatment

The Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion (BRAVO) study was a 6-month, phase III, randomized, injection-controlled trial, with an additional 6 months of follow-up (total 12 months), to evaluate the safety and efficacy of intraocular injections of 0.3 mg and 0.5 mg ranibizumab (an anti–vascular endothelial growth factor [VEGF] agent) in patients with macular edema following branch retinal vein occlusion (BRVO). The study showed that intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular adverse events. This study led to a paradigm shift toward anti-VEGF agents as the first-line treatment for macular edema secondary to BRVO.

scholarly journals The choice of treatment for macular edema following retinal vein occlusion

2015 ◽  
Vol 8 (4) ◽  
pp. 5-15
Author(s):  
Larisa Konstantinovna Moshetova ◽  
Tat'yana Vyacheslavovna Tsikhonchuk ◽  
Kseniya Ivanovna Turkina ◽  
Sergey Aleksandrovich Ignat'ev
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Disease Onset ◽  
Pathological Process ◽  
Intravitreal Injections ◽  
Vascular Endothelial ◽  
Vein Occlusion ◽  
Choice Of Treatment ◽  
Efficacy Assessment ◽  
Endothelial Growth Factor

A clinical efficacy assessment was performed for the therapy of post-occlusive cystoid macular edema using intravitreal anti-VEGF-ranibizumab injections at short and remote terms from the disease onset. It has been shown that ranibizumab intravitreal injections in retinal vein occlusion allow to increase visual acuity and to reduce retinal edema, and thus rehabilitate patients in maximally short terms. Intravitreal injections of vascular endothelial growth factor inhibitors at short terms from the disease onset allow achieving stabilization of the pathological process with preservation or improvement of visual functions, while reducing the number of repeated intravitreal injections.

scholarly journals Correlation between macular edema recurrence and macular capillary network destruction in branch retinal vein occlusion

2020 ◽  
Author(s):  
Ji Hye Jang ◽  
Yu Cheol Kim ◽  
Jae Pil Shin
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Bevacizumab ◽  
Capillary Network ◽  
Swept Source ◽  
Intravitreal Bevacizumab Injection ◽  
Vein Occlusion ◽  
Capillary Plexus ◽  
Recurrence Group

Abstract Background: The aim of this study was to evaluate the correlation between changes in the macular capillary network and macular edema (ME) recurrence with branch retinal vein occlusion (BRVO) using swept-source optical coherence tomography angiography (SS-OCTA). Methods: We reviewed the data for 43 patients with treatment-näive ME associated with BRVO. Patients who received intravitreal bevacizumab injection were divided into two groups based on ME recurrence at 6 months after edema resolution. The perifoveal capillary morphology and the macular capillary vessel density (VD) were retrospectively analyzed using en face SS-OCTA after ME resolution. Results: A broken the perifoveal capillary ring in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) was more common in the ME recurrence group (n=22) than in the no ME recurrence group (p = 0.047 and p = 0.002). Relative to the findings in the no ME recurrence groups, the destruction of the perifoveal capillary ring was more severe in the DCP (30.0° vs 87.3°, p = 0.001) than in the SCP (17.3° vs 69.5°, p = 0.006) in the ME recurrence group. The hemi-VD disparity between the affected and the unaffected areas in the SCP and DCP showed significant differences (p = 0.031 and p = 0.017), while macular VD showed no differences between the groups. Conclusions: Destruction of the perifoveal capillary ring and hemi-VD disparity could be related to ME recurrence in BRVO. Therefore, these factors may be helpful in predicting ME recurrence.

Sign in / Sign up

Export Citation Format

Share Document